Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 5/20 | 0.58 |
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.56 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345230 | 1.00 | KYNU (0.64) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL345229 | 1.00 | KYNU (0.64) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL6831659 | 0.94 | KYNU (0.59) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL1760460 | 0.94 | KYNU (0.59) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL6826924 | 0.94 | KYNU (0.59) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL8053250 | 0.91 | CTSL (0.65) | ALDH1A1ALOX15CTSKCTSSCTSL | |
| SCHEMBL2677964 | 0.91 | CTSK (0.57) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL7032185 | 0.91 | CTSK (0.57) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL17446717 | 0.91 | CTSK (0.57) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL13503284 | 0.89 | ALDH1A1 (0.64) | KYNUALDH1A1ALOX15CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909067-B | Organic total synthesis method of D-penicillamine | 浙江凯普化工有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-113773228-A | Synthesis method of N-benzyloxycarbonyl-3-iodo-L-alanine methyl ester | 上海吉奉生物科技有限公司 | 2021-12-10 | — | — | CN | claimed |
| CN-111909067-A | Organic total synthesis method of D-penicillamine | 浙江凯普化工有限公司 | 2020-11-10 | — | — | CN | claimed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12415789-B2 | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | AARHUS UNIVERSITET (DK) | 2025-09-16 | — | — | US | disclosed |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-02 | — | — | US | disclosed |
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-0669936-A1 | NOVEL MERCAPTOACETYLAMIDE BICYCLIC LACTAM DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL PHARMACEUTICALS INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| EP-0656210-A1 | Imidazole derivatives as glutaminose inhibitors | Takeda Chemical Industries, Ltd. (JP) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995003066-A1 | SELECTIVE MODIFICATION OF THE CARBOXY THERMINUS OF A PROTEIN | PERKIN-ELMER CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
| WO-1994010193-A1 | NOVEL MERCAPTOACETYLAMIDE BICYCLIC LACTAM DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994001421-A1 | BENZOTHIAZEPINE AND BENZOXAZEPINE DERIVATIVES AS CHOLECYSTOKININ RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| EP-0123442-B1 | IMPROVEMENTS IN OR RELATING TO A PROCESS FOR PRODUCING BETA-LACTAM COMPOUNDS | THE UNIVERSITY OF NOTRE DAME DU LAC (US) | 1988-06-15 | — | — | EP | disclosed |
| US-4675399-A | N-HYDROXY-2-AZETIDINONES; ACYLATION, SOLVOLYSIS | NOTRE DAME UNIVERSITY (US) | 1987-06-23 | — | — | US | disclosed |
| US-4565654-A | BETA-LACTAMASE ENZYME INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1986-01-21 | — | — | US | disclosed |
| EP-0123442-A1 | Improvements in or relating to a process for producing beta-lactam compounds | THE UNIVERSITY OF NOTRE DAME DU LAC (US) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | KYNU 462/4885ALDH1A1 2208/4885ALOX15 899/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | KYNU 1736/4885ALDH1A1 3293/4885ALOX15 2204/4885 |
| US-12358951-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | KYNU 2630/4885ALDH1A1 4279/4885ALOX15 3457/4885 |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | KYNU 1983/4885ALDH1A1 2383/4885ALOX15 1081/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | KYNU 1211/4885ALDH1A1 3564/4885ALOX15 815/4885 |
| US-12415789-B2 | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | DLD, HIF1A, DPYD | KYNU 1551/4885ALDH1A1 386/4885ALOX15 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.